Announcement
Login
We offer our registered users tailored information, free online courses and exclusive content.
Can't find your password?
Reset it here.
Reset it here.
Learning Package: Biomarker-driven therapeutic strategies in mCRC
Learning Package: Biomarker-driven therapeutic strategies in mCRC
- Oncology
13 February 2018
Usage
Practical
As the number of therapeutic options for metastatic colorectal cancer increases, insights into the biology of the disease and biomarker-driven therapeutic strategies are expected to improve patient survival and rationalize therapeutic approaches. Review the slide kits below for updates on treating mCRC.
Molecular pathology and biomarkers
Critical pathways in metastatic colorectal cancer (mCRC)
A. Sobrero (Italy)
Molecular biomarkers for mCRC
A. Sobrero (Italy)
Evidence-based recommendations for molecular testing of mCRC
C.H. Köhne (Germany)
Tumor heterogeneity and blood-based biomarkers
J. Taieb (France)
Treatment decisions in metastatic colorectal cancer (I)
RAS Wild-type and BRAF Wild-type mCRC
A. Sobrero (Italy)
Primary tumor location of RAS wild-type mCRC: left vs right
C.H. Köhne (Germany)
RAS mutated and BRAF mutated mCRC
J. Taieb (France)
Treatment decisions in metastatic colorectal cancer (II)
Oligometastatic disease
C.H. Köhne (Germany)
Therapy after progression
J. Taieb (France)
Spotlight - Molecular classification of CRC
C.H. Köhne (Germany)
Spotlight - Immunotherapy for mCRC
J. Taieb (France)
Regional workshop
United Arab Emirates
Dec 21 - 22, 2017
Target audience
This programme is intended for oncologists and practicing clinicians who have an interest in understanding colorectal cancer biology and building individual competencies in the management of the disease.
by Excemed
Oncology